UNICREDIT BANK/CALL/BIOGEN IDEC/320/0.1/14.01.26 | Market Closed - BOERSE MUENCHEN 03:41:34 2024-06-13 pm EDT | ||
| 2.27 EUR | +4.61% |
|
| Current month | +8.10% | ||
| 1 month | +14.65% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-06-13 | 2.27 | +4.61% |
| 24-06-12 | 2.17 | +3.83% |
| 24-06-11 | 2.09 | +0.97% |
| 24-06-10 | 2.07 | +0.49% |
| 24-06-07 | 2.06 | -10.43% |
Real-time BOERSE MUENCHEN
Last update June 13, 2024 at 03:41 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD4WFT |
| ISIN | DE000HD4WFT2 |
| Date issued | 2024-04-22 |
| Strike | 320 $ |
| Maturity | 2026-01-14 (580 Days) |
| Parity | 10 : 1 |
| Emission price | 1.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.46 € |
|---|---|
| Lowest since issue | 1.07 € |
| Spread | 0.06 € |
| Spread % | 2.55% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
233.8
USD
Average target price
284.6
USD
Spread / Average Target
+21.73%
- Stock Market
- Warrants
- Warrant
